Senate committee targets Valeant and Turing Pharma; House Democrats lean on Republican committee leadership to act
A day after the White House, via HHS, set up a public airing of pricing-related issues, the Senate Special Committee on Aging, led by Susan Collins (R-ME) and with Democratic support, sent a long list of document requests to Valeant Pharma, Turing Pharma, Retrophin and Rodelis Therapeutics. Each letter seeks documents and communications that could be documented, on how these companies had made decisions to raise prices of various drugs by hundreds to thousands of percentage points in recent months. The requests are specific to certain drugs: Nitropress, Isuprel and Cuprimine (Valeant); Daraprim (Turing); Thiola (Retrphin); and Seromycin (Rodelis). All of these drugs are off patent, but only a few have sourcing alternatives to the named companies.
On the House side, all 18 of the Democrats on the House Committee on Oversight and Government Reform, led by ranking member Elijah Cummings (D-MD), held a press conference to publicize a letter sent to the committee chair, Jason Chaffetz (R-UT). They want to schedule a committee vote to issue subpoenas to J. Michael Pearson, chairman of Valeant, and Martin Shkreli, CEO of Turing, “to produce documents they have been withholding from Congress about the skyrocketing prices of their prescription drugs.” The Democratic committee members have been agitating for action since September; both companies had declined to comply with previous requests.
It’s hard to tell, short of subpoenas and subsequent legal actions, what either committee can do to obtain the documents; also, Valeant is already under investigation by federal prosecutors. It’s worth noting that one of the proposals floated in September by the Center for American Progress, a progressive think tank, is to require public disclosure of pricing analysis under certain circumstances.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.